Genitourinary cancers are found in urinary tract (kidney and bladder) and male reproductive system (prostate, testicles and penis).
Biography
Dr Mitchell Lawrence is a Senior Research Fellow at Monash University with a part-time appointment at Peter Mac since 2017. His expertise includes the use of human preclinical models to study tumour biology, pathology, and novel therapies. In particular,
Dr Lawrence uses patient-derived xenografts (PDXs) and organoids from the Melbourne Urological Research Alliance (MURAL). These models represent the clinico-pathological and genomic spectrum of prostate cancer, from treatment-naïve primary tumors to castration-resistant metastases. For these multidisciplinary studies, Dr Lawrence works with a diverse team of collaborators, including urologists, oncologists, pathologists, bioinformaticians and patient advocates.
Dr Lawrence also collaborates with A/Prof Kaylene Simpson and the team from the Victorian Centre for Functional Genomics to develop high-throughput 3D assays with prostate cancer cells.
Qualifications
BAppSc (Hons), PhD
Publications
https://pubmed.ncbi.nlm.nih.gov/34413304/
This manuscript reports 59 new patient-derived models of prostate cancer from the Melbourne Urological Research Alliance
https://pubmed.ncbi.nlm.nih.gov/34413130/
This study used xenografts and organoids to demonstrate that combination therapy increases the effectiveness of PARP inhibitors for treating castration-resistant prostate cancer
https://pubmed.ncbi.nlm.nih.gov/34111999/
This collaborative study with the Victorian Centre for Functional Genomics developed a new assay for analysing the responses of 3D organoids of prostate cancer cells to candidate therapies
https://pubmed.ncbi.nlm.nih.gov/33620092/
This paper reports a new set of patient-derived models spanning the progression from castration sensitive localised prostate cancer to castration-resistant metastatic disease.
https://pubmed.ncbi.nlm.nih.gov/32132214/
This article discussed the importance of ductal and intraductal pathologies of primary prostate cancer as markers of poor prognosis.
